Oxaliplatin Kalceks

Oxaliplatin, the active ingredient in Oxaliplatin Kalceks, is a platinum‑based chemotherapy presented as a strength/form for intravenous use. It treats colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin Kalceks is a platinum‑based chemotherapeutic agent used in the treatment of cancers that arise from the gastrointestinal tract.

- Colorectal cancer: Enhances tumor response when combined with fluoropyrimidine‑based regimens. - Gastric cancer: Contributes to disease control as part of combination chemotherapy. - Pancreatic cancer: Used in multi‑drug protocols to improve progression‑free survival. - Esophageal cancer: Added to standard regimens to increase overall response rates. - Metastatic adenocarcinoma of the colon: Provides additional cytotoxic activity in refractory cases.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, requiring monitoring throughout therapy.

Common Side Effects: - Peripheral neuropathy: Tingling or numbness, often dose‑dependent. - Nausea and vomiting: May require anti‑emetic prophylaxis. - Diarrhea: Can be self‑limiting or require supportive care. - Fatigue: Generalised tiredness affecting daily activities. - Thrombocytopenia: Reduced platelet count, increasing bleed risk. - Elevated liver enzymes: Transient rise in AST/ALT.

Serious or Rare Side Effects: - Severe neuropathy: Persistent sensory loss that may be irreversible. - Acute allergic reactions: Rash, bronchospasm, or anaphylaxis. - Hematologic toxicity: Neutropenia or anemia requiring intervention. - Cardiotoxicity: Rare arrhythmias or myocardial injury. - Renal impairment: Acute kidney injury in susceptible patients.

Oxaliplatin should be administered under the supervision of an experienced oncology team, with attention to patient‑specific risk factors and monitoring requirements.

- Renal function: Assess baseline creatinine and adjust if impaired. - Hepatic function: Monitor liver enzymes before each cycle. - Neuropathy risk: Evaluate pre‑existing peripheral neuropathy and adjust dosing. - Pregnancy and lactation: Contra‑indicated unless benefits outweigh risks. - Concomitant ototoxic drugs: Use caution when combined with other neurotoxic agents. - Store at below 25°C: Keep in original packaging, protect from moisture and light.

Oxaliplatin may interact with several drug classes, influencing efficacy or toxicity. Careful review of the patient's medication list is essential.

Major Interactions (Avoid): - Nephrotoxic agents: Concurrent use can exacerbate renal injury. - Highly protein‑bound drugs: May displace oxaliplatin, altering free drug levels.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): May affect oxaliplatin clearance. - Anticoagulants: Increased bleeding risk with thrombocytopenia. - CYP450 inducers/inhibitors: Potentially modify metabolic pathways. - Radiotherapy: May enhance neurotoxic effects when combined. - Herbal supplements: Unpredictable effects on drug metabolism.